Published in Aging health on December 01, 2008
Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis (2015) 2.96
HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ (2010) 1.98
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One (2011) 1.43
Aging with HIV in Africa: the challenges of living longer. AIDS (2012) 1.21
HIV and Menopause: A Systematic Review of the Effects of HIV Infection on Age at Menopause and the Effects of Menopause on Response to Antiretroviral Therapy. Obstet Gynecol Int (2013) 0.89
A missing piece in the puzzle: HIV in mature adults in sub-Saharan Africa. Future Virol (2011) 0.87
Decreased chronic morbidity but elevated HIV associated cytokine levels in HIV-infected older adults receiving HIV treatment: benefit of enhanced access to care? PLoS One (2013) 0.86
Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? Indian J Med Res (2011) 0.84
Polypharmacy in the HIV-infected older adult population. Clin Interv Aging (2013) 0.83
HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. AIDS Res Hum Retroviruses (2014) 0.81
A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV. HIV AIDS (Auckl) (2013) 0.78
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort. PLoS One (2017) 0.75
Characteristics and outcomes of older HIV-infected patients receiving antiretroviral therapy in Malawi: A retrospective observation cohort study. PLoS One (2017) 0.75
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci (2001) 42.21
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA (2005) 20.53
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 7.65
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med (2003) 5.88
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 5.49
Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst (2001) 5.03
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis (2000) 3.81
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis (2005) 3.76
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology (2004) 3.44
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 3.41
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr (2002) 3.33
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis (2007) 3.02
Increased COPD among HIV-positive compared to HIV-negative veterans. Chest (2006) 2.93
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis (2005) 2.92
Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med (1987) 2.91
Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care (2006) 2.82
HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci (2007) 2.75
Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 2.50
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin (2005) 2.35
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Adverse drug reaction (ADR) occurrence and evaluation in elderly inpatients. Pharmacoepidemiol Drug Saf (1996) 2.28
Survival trends for patients with AIDS. JAMA (1990) 2.24
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis (2003) 2.17
Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health (2003) 2.16
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation (2004) 2.16
Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med (2007) 2.07
Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol (2005) 1.94
AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med (1994) 1.94
Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr (2004) 1.93
A framework for tailoring clinical guidelines to comorbidity at the point of care. Arch Intern Med (2007) 1.92
HIV infection in older patients in the HAART era. J Antimicrob Chemother (2005) 1.90
Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr (2003) 1.83
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS (2003) 1.77
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.71
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (2004) 1.67
General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol (2001) 1.67
AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr (2003) 1.58
AIDS-related Pneumocystis carinii pneumonia in older patients. J Gen Intern Med (1996) 1.54
Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS (2004) 1.54
Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med (1995) 1.48
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr (1994) 1.43
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis (2004) 1.43
Reduced aerobic capacity and physical functioning in older HIV-infected men. AIDS Res Hum Retroviruses (2006) 1.40
Provision of general and HIV-specific health maintenance in middle aged and older patients in an urban HIV clinic. AIDS Patient Care STDS (2006) 1.37
Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol (2001) 1.35
Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS (2008) 1.34
The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med (1996) 1.34
AIDS among persons aged > or = 50 years--United States, 1991-1996. MMWR Morb Mortal Wkly Rep (1998) 1.33
More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr (1991) 1.26
HIV infection, drug use, and onset of natural menopause. Clin Infect Dis (2005) 1.24
Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med (1995) 1.24
Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS (2001) 1.23
Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med (2006) 1.22
Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis (2005) 1.22
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis (2004) 1.18
A prospective study of factors affecting age at menopause. J Clin Epidemiol (1989) 1.18
HIV infection and advanced age emerging epidemiological, clinical, and management issues. Ageing Res Rev (2004) 1.18
Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med (2006) 1.16
Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.16
Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol (1990) 1.14
Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med (2007) 1.14
Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging (2003) 1.12
Epidemiology of acquired immune deficiency syndrome in persons aged 50 years or older. J Acquir Immune Defic Syndr (1991) 1.11
A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS (2000) 1.10
Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis (2007) 1.09
HIV infection in patients over 55 years of age. J Acquir Immune Defic Syndr (1992) 1.08
HIV disease and advanced age: an increasing therapeutic challenge. Drugs Aging (2002) 1.06
The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr (2003) 1.05
Older age and plasma viral load in HIV-1 infection. AIDS (2004) 1.04
The changing epidemiology of human immunodeficiency virus infection in older persons. J Am Geriatr Soc (1995) 1.02
The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS (1990) 1.01
Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis (2002) 1.01
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis (2003) 1.00
Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis (2003) 1.00
Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr (2003) 0.99
The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med (2008) 0.99